News Releases

Second quarter revenues of $2.76 billion, up 15.2% from 2024 Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5%...

Diagnostic testing for emerging infectious disease associated with severe neurological affects SECAUCUS, N.J., July 15, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic...

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J.,...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today published its 2024 Corporate Responsibility Report. The theme of the report, Care Starts Here, reflects the...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2025 financial results on Tuesday, July 22, 2025, before the...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) designed...

Quest's second "Know Your Health" survey explores Americans' perceptions and priorities on their well-being in 2025 Nearly one-third of Americans say their doctors/HCPs do not take the time to...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21,...

More than 3 in 4 oncologists (76%) feel they are seeing more advanced cancers, and of these, 75% believe that screening barriers are the leading cause, although nearly one-third (32%) cite...